Search Results for: stem cell biotech

Anti-cure impact of Errant EU stem cell patent decision

There has been concern for months about the direction that the European Union was heading in regards to intellectual property (IP) rights and stem cell patent approaches. Now, a definitive decision banning embryonic stem cell (ESC)-based patents by the EU Court has dealt a severe blow to stem cell science in Europe. The European Court […]

Anti-cure impact of Errant EU stem cell patent decision Read More »

Everything you need to know about publishing in the iPS cell field

I have posted before about publishing trends in the iPS cell field here and in here…. but where do things stand today? Here, I provide an important update. What’s going on now? Here I provide answers to the key questions.   How many papers are there on iPS cells? An interesting and unexpected trend for

Everything you need to know about publishing in the iPS cell field Read More »

Clinical Trials Part II: Viacyte Director of Stem Cell Research Dr. D’Amour speaking today in Seattle

Viacyte is one of the most exciting biotechs in the stem cells for diabetes space. Dr. Kevin D’Amour, Director of Stem Cell Research at Viacyte, gave an excellent, extremely interesting talk Friday morning: Developing an Encapsulated Stem Cell Therapy for Diabetes. Viacyte talk In the talk, Dr. D’Amour gave a very detailed description of their

Clinical Trials Part II: Viacyte Director of Stem Cell Research Dr. D’Amour speaking today in Seattle Read More »

Why invest in stem cells? Progress, Patients, and Patents

Why invest in stem cells? Ideas are the foundation of stem cell research, but funding makes those ideas a reality. We talk a lot about governmental funding of stem cell research through CIRM and NIH. The funding from these agencies is essential and will undoubtedly lead to new treatments and cures, possibly for millions of

Why invest in stem cells? Progress, Patients, and Patents Read More »

Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs

Who’s who in the field of iPS cells?  In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field.  It suggested that the iPS cell field was

Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »

iPS cells coming into focus: not quite so similar to ESC after all

FaviconIPSCELL

Update in 2020: It seems now after all these years that the consensus in the now more mature field is that IPSCs and ESCs are nearly identical in most cases, and both have some of the same translational challenges such as teratoma-forming activity. It’s interesting to read this post from nearly 10 years ago and

iPS cells coming into focus: not quite so similar to ESC after all Read More »